Johnson & Johnson Forms Product Distribution Partnerships with AbbVie and Genmab
What happened
Johnson & Johnson announced product distribution partnerships with AbbVie and Genmab. Johnson & Johnson distributes its products directly to wholesalers and hospitals, a process that is bolstered by these collaborations.
From fool.com
Why it matters
Johnson & Johnson operates through two primary segments: innovative medicine and medtech. These distribution partnerships expand the reach of the companies' products across the global market.
From fool.com
Who's involved
- Johnson & JohnsonManufacturer and distributor of medical devices and pharmaceuticals
- AbbViePartner in the product distribution agreement
- GenmabPartner in the product distribution agreement
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Johnson & JohnsonSpeculative
Johnson & Johnson might see increased revenue through its supply chain.
- AbbVieSpeculative
AbbVie could see increased revenue through its supply chain.
- GenmabSpeculative
Genmab could see increased revenue through its supply chain.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
AbbVie
pharmaceutical company
-
Genmab
Danish healthcare company
Nothing else this week.
Related events
- Johnson & Johnson operates a business unit focused on surgical and orthopedic equipment.
- Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.
- Major pharmaceutical companies, including Eli Lilly, Johnson & Johnson, and AbbVie, are significant holdings in various health care ETFs.
- United Therapeutics and Johnson & Johnson are both included in various healthcare Exchange Traded Funds (ETFs).
- JNJ shares were upgraded following positive developments regarding the company's new drug pipeline.